Form 13-F position report

ARROWHEAD PHARMACEUTICALS INC

Reported by M28 Capital Management LP

ARWR CUSIP 04280A100 Manager CIK 0001807489

Reported 67,400 shares, unchanged from the prior quarter.

Reported value -32.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 1.18% This manager · Q1 2025
Shares 67,400 Quarter-end amount reported
Reported value $858,676 Fair value at quarter end
Consecutive quarters held 10 Through Q1 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-12-31 5836584
2023-03-31 1711960
2023-06-30 2403484
2023-09-30 1811038
2023-12-31 2062440
2024-03-31 1927640
2024-06-30 1751726
2024-09-30 1305538
2024-12-31 1267120
2025-03-31 858676
2025-06-30 1064920
2025-09-30 2324626
2025-12-31 4474686
2026-03-31 2310558
2026-06-30 3003725

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for ARROWHEAD PHARMACEUTICALS INC held by M28 Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2026 Unchanged 36,851 0 (0.0%) 6.37% $3,003,725 2026-08-13
Q1 2026 Reduced 36,851 -30,549 (-45.3%) 4.29% $2,310,558 2026-05-14
Q4 2025 Unchanged 67,400 0 (0.0%) 3.25% $4,474,686 2026-02-13
Q3 2025 Unchanged 67,400 0 (0.0%) 3.42% $2,324,626 2025-11-13
Q2 2025 Unchanged 67,400 0 (0.0%) 1.82% $1,064,920 2025-08-13
Q1 2025 Unchanged 67,400 0 (0.0%) 1.18% $858,676 2025-05-14
Q4 2024 Unchanged 67,400 0 (0.0%) 1.24% $1,267,120 2025-02-13
Q3 2024 Unchanged 67,400 0 (0.0%) 1.43% $1,305,538 2024-11-12
Q2 2024 Unchanged 67,400 0 (0.0%) 2.27% $1,751,726 2024-08-13
Q1 2024 Unchanged 67,400 0 (0.0%) 1.42% $1,927,640 2024-05-14
Q4 2023 Unchanged 67,400 0 (0.0%) 1.71% $2,062,440 2024-02-12
Q3 2023 Unchanged 67,400 0 (0.0%) 2.08% $1,811,038 2023-11-13
Q2 2023 Unchanged 67,400 0 (0.0%) 3.18% $2,403,484 2023-08-11
Q1 2023 Reduced 67,400 -76,500 (-53.2%) 1.94% $1,711,960 2023-05-12
Q4 2022 New 143,900 +143,900 (0.0%) 5.56% $5,836,584 2023-02-10

Who else reported the position

312 managers reported ARROWHEAD PHARMACEUTICALS INC for Q1 2025.

Managers reporting ARROWHEAD PHARMACEUTICALS INC in Q1 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 19,926,154 +3,748,154 < 0.01% $253,859,202 3 qtrs
VANGUARD GROUP INC Added 13,202,562 +1,018,273 < 0.01% $168,200,640 36 qtrs
Avoro Capital Advisors LLC Unchanged 11,111,111 0 2.21% $141,555,554 8 qtrs
STATE STREET CORPORATION Added 6,999,249 +983,022 < 0.01% $89,170,432 37 qtrs
Slate Path Capital LP Unchanged 5,232,000 0 1.2% $66,655,680 6 qtrs
UBS ASSET MANAGEMENT AMERICAS INC Added 4,785,062 +2,774,933 0.02% $60,961,689 28 qtrs
FMR LLC Reduced 3,315,082 -1,786,001 < 0.01% $42,234,145 27 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,950,312 -4,635 < 0.01% $37,595,616 36 qtrs
Siren L L C Reduced 2,669,880 -231,801 1.92% $34,014,271 3 qtrs
T Rowe Price Investment Management Inc Added 2,528,982 +21,686 0.02% $32,220,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2025
Filed
May 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
67,400
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.